Description
This 12-week learning collaborative will serve as a virtual community for participants to gain knowledge of evidence-based principles for prescribing clozapine for patients with serious mental illness (SMI). Clozapine can be very rewarding to prescribe, since about half of patients with prior poor treatment response get substantially better with clozapine. This medication can result in major improvements in patients’ functioning and quality of life.
Program Schedule
The facilitated 12-week syllabus will be held from April 1 to June 30, 2023. No content will be released during the week of May 6, 2024.
Please note you must complete all 13 modules in order to claim credit for this course.
|
Module Opens
|
Week
|
Description
|
Office Hours
|
|
Mar 25
|
0
|
Pre-work: Welcome and Introduction
|
---
|
|
Apr 1
|
1
|
Clozapine Overview: Efficacy and Mechanism of Action
|
|
|
Apr 8
|
2
|
Pharmacokinetics and Interpreting Clozapine levels
|
Wed, 4/10 @ 3:00-3:30pm ET
|
|
Apr 15
|
3
|
Hematological Considerations and Side Effects
|
|
|
Apr 22
|
4
|
Metabolic Considerations and Side Effects
|
Wed 4/24 @ 3:00-3:30pm ET
|
|
Apr 29
|
5
|
Cardiac Considerations and Side Effects
|
|
|
May 13
|
6
|
GI Considerations and Side Effects
|
Wed, 5/15 @ 3:00-3:30 pm ET
|
|
May 20
|
7
|
Other Side Effects (Sialorrhea, Pneumonia, VTE, Enuresis)
|
|
|
May 27
|
8
|
Neurological Side Effects
|
Wed, 5/29 @ 3:00-3:30 pm ET
|
|
Jun 3
|
9
|
Managing Partial Response and Treatment Resistance
|
|
|
Jun 10
|
10
|
Team-based approaches to clozapine (e.g., clozapine clinics)
|
Wed, 6/12 @ 3:00-3:30pm ET
|
|
Jun 17
|
11
|
Measuring side effects
|
|
|
Jun 24
|
12
|
Presentation of SE monitoring protocol
|
Wed, 6/26 @ 3:00-4:00pm ET (1 hour)
|
|
Jun 30
|
X
|
Program Schedule/Syllabus Ends
|
|
Pricing
FREE - $0
Learning Objectives
- Identify patients who are appropriate candidates for clozapine
- Evaluate the balance between clozapine and efficacy for control of psychiatric symptoms with that of common side effects.
- Review major organ systems for how to assess and mitigate clozapine side effects
- Develop and implement a scale to monitor for side effects for patients taking clozapine.
Target Audience
Clinicians that are prescribing clozapine to individuals with SMI. [MD/DO, PMHNP, PMH-RN, PA]
Instructional Level
Introductory; Intermediate
Estimated Time to Complete
Estimated Duration: 15.0 hours
Program Start Date: April 1, 2024
Program End Date: June 30, 2024
Credit Available Until: August 29, 2024
How to Earn Credit
Participants who wish to earn continuing medical education (CME) or a certificate of participation may do so by completing all sections of the course including the program evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (other professions) showing the date of completion and hours earned.
Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The APA designates this blended activity for a maximum of 15.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Instructor/Planner
- Robert O. Cotes, MD. Emory University School of Medicine. Disclosures – Consultant: Saladax Biomedical, HLS Therapeutics (unpaid); Research funding (to institution): Otsuka, Roche, Karuna, Alkermes. Speaker: Clinical Care Options.
Planners
- John Torous, MD, Beth Israel Deaconess Medical Center. Dr. Torous has no relevant financial relationships to disclose.
- Teri Brister, PHD, LPC, National Alliance for Mental Illness. Dr. Brister has no relevant financial relationships to disclose.
- Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC, University of Texas School of Nursing. Dr. Rolin has no relevant financial relationships to disclose.
- Robert O. Cotes, MD. Emory University School of Medicine. Disclosures – Consultant: Saladax Biomedical, HLS Therapeutics (unpaid); Research funding (to institution): Otsuka, Roche, Karuna, Alkermes. Speaker: Clinical Care Options.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.